HC Wainwright & Co. Reiterates Buy on Immunovant, Maintains $35 Price Target
Benzinga Newsdesk 8 months ago
NewsPrice TargetReiterationAnalyst Ratings
HC Wainwright & Co. analyst Douglas Tsao reiterates Immunovant (NASDAQ:IMVT) with a Buy and maintains $35 price target.
HC Wainwright & Co. analyst Douglas Tsao reiterates Immunovant (NASDAQ:IMVT) with a Buy and maintains $35 price target.